Show notes
Prohibition cannot eliminate consumer demand. It’s an iron rule of free markets. As lower-risk nicotine products remain stuck under FDA review, illicit products proliferate to fill the void. Shot on location at GFN 2026 in Warsaw, Poland, Altria’s Dr. Mohamadi Sarkar argues that slow authorization decisions have left regulators playing enforcement “whack-a-mole” while adult smokers wait for more FDA-authorized alternatives.Featuring:DR. MOHAMADI SARKARRegulatory Science & Engagement, AltriaAffiliate Prof., Clinical Pharmacology, VCU@AltriaScience



